Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced its earnings for the first quarter of FY25. The company posted a revenue of Rs. 720 crore in Q1 FY25 as compared to Rs. 467 crore in Q1 FY24, reflecting a growth of 54 per cent. The company’s gross profit jumped by 39 per cent at Rs. 539 crore in Q1 FY25 from Rs. 388 crore in Q1 FY24. However, PAT in Q1 FY25 dropped 4.5 per cent at Rs. 89 crore from Rs. 94 crore during Q1 FY24.

Commenting on the results, Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “We have integrated the Biocon acquisitions well ahead of schedule and started realising significant synergies in our flagship Domestic Branded Formulations business, which accounts for 90% of our revenue. We expect to clock a growth of 25% plus in the Biocon business in FY25 with significant margin expansion. Our business model has evolved from “specialty” to a “specialty plus super-specialty” model with the addition of segments such as Insulins, Oncology, Critical Care and Nephrology. As a Top-20 company in the IPM, we are taking tangible initiatives to step up our game in the Biotechnology space as well.”

Q1FY25 - Business Highlights

* Domestic Branded Formulations segment revenue grew by 39% yoy and EBITDA grew by 34%

* Eris now ranks among the Top-20 companies in the Indian Pharmaceutical Market (as per AWACS)

* Q1 growth for Eris is 12.7% vs. CVM growth of 8.1%: Eris is ahead of market by 460 bps and has shown market-beating growth in 4 out of its top 6 therapies (as per AWACS)

*  Eris ranks 3rd in the IPM in terms of New Products Count and Value (as per AWACS)